Open-label Study of Dupilumab in Patients With Atopic Dermatitis
Status:
Active, not recruiting
Trial end date:
2022-07-12
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the long-term safety of dupilumab administered in adult
participants with atopic dermatitis (AD).
The secondary objective of the study is to assess the immunogenicity of dupilumab in adult
participants with AD, in the context of re-treatment, and to monitor efficacy parameters
associated with long-term treatment.
Optional Sub-Study:
The primary objective of the sub-study is to assess the safety of the new dupilumab drug
product in adult patients with AD after switching from the current dupilumab drug product.
The secondary objectives of the sub-study are to evaluate systemic exposure and
immunogenicity of the new dupilumab drug product in adult patients with AD.